Nema internetske veze — prikazuje se spremljena verzija stranice.

Mesoblast Ltd

USUSD
← Na filtar dionica

Mesoblast Ltd (AU:MSB) — Biotechnology: Biological Products (No Diagnostic Substances). Broj burzi na kojima se trguje dionicama tvrtke: 2. Na ovoj stranici — cijena i grafikon, dividende, najveći dioničari i povijest broja dionica.

O tvrtki

Web-stranica
mesoblast.com
Sektor
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Sjedište
MELBOURNE, VICTORIA, Australia
Glavni direktor
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)
Zaposlenici
108
Dionice u optjecaju
1.3 mlrd. na dan 2026-06-30
Slobodno prenosive dionice
861.1 mil.
Tržišna kapitalizacija
1.48 mlrd. USD
Insajderi
36.28%
Institucionalni ulagači
17.44%
Djelatnost (SIC)
Biological Products, (No Diagnostic Substances)
ISIN
AU000000MSB8
Opis

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.

Burze i oznake

BurzaOznakaValutaCijenaVrsta
US USA StocksMEOBF OTCUSD1.39 +21.93%obične dionice
AU Australian Securities ExchangeMSB glavnaAUD2 +3.36%obične dionice

Cijena za 3 mjeseca

dan rasta dan pada ex-dividendni datum datum isplatePrijeđite mišem / dodirnite dan — cijene otvaranja, zatvaranja, najviša i najniža

Dividende

Isplate dividendi nisu pronađene (provjereno 09.10.2026). Tvrtka vjerojatno ne isplaćuje dividende.

Vijesti ovog tjedna

Još nema vijesti s web-stranice tvrtke.

oglas

Najveći imatelji

ImateljUdioDioniceDatum izvješća
Itescu (Silviu) (Chief E…≈6.23%80.84 mil.2026-07-17
VANGUARD STAR FUNDS-Vang…1.05%13.66 mil.2026-04-30
VANGUARD TAX-MANAGED FUN…0.62%8.01 mil.2026-06-30
iShares Trust-iShares Co…0.53%6.88 mil.2026-07-31
Rose (Eric) (Director (N…≈0.52%6.75 mil.2026-01-09
DFA INVESTMENT TRUST CO-…0.36%4.68 mil.2026-04-30
VANGUARD Intl Eqy. INDEX…0.27%3.51 mil.2026-04-30
iShares Trust-iShares MS…0.24%3.07 mil.2026-07-31
SCHWAB STRATEGIC TRUST-S…0.15%1.99 mil.2026-05-31
Dimensional ETF Trust-Di…0.11%1.38 mil.2026-04-30
iShares Trust-iShares Co…0.09%1.23 mil.2026-07-31
SPDR INDEX SHARES Fd.S-S…0.09%1.19 mil.2026-08-31
Bell (Jane Catherine) (D…≈0.05%622 4922025-02-28
Burns (William) (Indepen…≈0.02%226 2502025-10-21
Legato Capital Managemen…0.01%47 3802022-06-30
Cobley (Lyn Elizabeth) (…≈0%63 0002026-01-09